Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 5/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351232 | 0.74 | ARG1 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL9658075 | 0.74 | ARG1 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL2071540 | 0.72 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL17740136 | 0.72 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL978535 | 0.72 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL17740138 | 0.72 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL15571615 | 0.72 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL2032498 | 0.72 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL2806367 | 0.66 | SLC1A2 (0.59) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL11511876 | 0.66 | SLC1A2 (0.59) | ARG1SLC1A2MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ARG1 2747/4885SLC1A2 1691/4885MEN1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.